Oncolytic Virus Therapies Market by Virus Type (Genetically Engineered Oncolytic Viruses, Oncolytic Wild-Type Viruses), Application (Solid Tumors, Melanoma), End Use (Hospitals, Specialty Clinics, Cancer Research Institute), and Region 2023-2028

Oncolytic Virus Therapies Market by Virus Type (Genetically Engineered Oncolytic Viruses, Oncolytic Wild-Type Viruses), Application (Solid Tumors, Melanoma), End Use (Hospitals, Specialty Clinics, Cancer Research Institute), and Region 2023-2028

The global oncolytic virus therapies market size reached US$ 130.4 Million in 2022. Looking forward, IMARC Group expects the market to reach US$ 492.6 Million by 2028, exhibiting a growth rate (CAGR) of 20.90% during 2023-2028.

Oncolytic virus therapies are a form of immunotherapy that utilizes viruses to infect and destroy cancer cells. They use various natural and genetically modified viruses, such as herpes simplex, Newcastle disease, vaccinia, adenovirus, reovirus, and picornavirus. Oncolytic virus therapies activate danger signals for generating an immune response and are widely used for treating solid tumors, melanoma, and unresectable lesions. They also help eradicate tumors using viruses that only infect and destroy targeted tumor cells. As compared to chemotherapy, oncolytic virus therapies are non-toxic, provide superior efficacy, and prolong the survival of cancer patients. As a result, they find extensive applications in hospitals, clinics, and cancer research institutes.

Oncolytic Virus Therapies Market Trends:
The rising incidences of cancer across the globe are creating a positive outlook for the market. Oncolytic virus therapies are widely used to treat various cancers, such as glioblastoma, breast, lung, and prostate cancers, due to their powerful anti-tumor properties and ability to target tumors accurately without harming surrounding tissues. In line with this, the widespread utilization of the therapy to treat various types of melanomas, such as hematological malignancies, lymphoma, leukemia, and myeloma, is favoring the market growth. Furthermore, rising concerns among patients regarding the negative health impact of various cancer treatments, such as surgical intervention, radiotherapy, chemotherapy, and immunotherapy, are providing a considerable boost to the market growth. Additionally, the rising number of clinical studies in oncolytic viruses, such as herpesvirus, adenovirus, and vaccinia virus, that is in the final stages and have demonstrated excellent experimental results are facilitating the market growth. Other factors, including rising demand for advanced treatments and novel therapies and increasing initiatives by several governments to spread awareness regarding different causes of cancer and promote early diagnosis, are anticipated to drive the market growth.

Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global oncolytic virus therapies market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on virus type, application and end use.

Breakup by Virus Type:

Genetically Engineered Oncolytic Viruses
Herpes Simplex Virus
Adenovirus
Vaccinia Virus
Oncolytic Wild-Type Viruses
Reovirus
Newcastle Disease Virus
Vesicular Stomatitis Virus

Breakup by Application:

Solid Tumors
Breast Cancer
Prostate Cancer
Lung Cancer
Glioblastoma
Melanoma
Hematological Malignancies
Lymphoma
Leukemia
Myeloma

Breakup by End Use:

Hospitals
Specialty Clinics
Cancer Research Institute

Breakup by Region:

North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa

Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Amgen Inc., Dnatrix Inc., Genelux Corporation, Lokon Pharma AB, Replimune Group Inc., Rigvir Ltd., Sorrento Therapeutics, Takara Bio Inc. (Takara Holdings Inc.), Targovax, TILT Biotherapeutics Ltd, Transgene SA and Vyriad. Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report
1. What was the size of the global oncolytic virus therapies market in 2022?
2. What is the expected growth rate of the global oncolytic virus therapies market during 2023-2028?
3. What are the key factors driving the global oncolytic virus therapies market?
4. What has been the impact of COVID-19 on the global oncolytic virus therapies market?
5. What are the key regions in the global oncolytic virus therapies market?
6. Who are the key players/companies in the global oncolytic virus therapies market?


1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Oncolytic Virus Therapies Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Virus Type
6.1 Genetically Engineered Oncolytic Viruses
6.1.1 Market Trends
6.1.2 Key Segments
6.1.2.1 Herpes Simplex Virus
6.1.2.2 Adenovirus
6.1.2.3 Vaccinia Virus
6.1.3 Market Forecast
6.2 Oncolytic Wild-Type Viruses
6.2.1 Market Trends
6.2.2 Key Segments
6.2.2.1 Reovirus
6.2.2.2 Newcastle Disease Virus
6.2.2.3 Vesicular Stomatitis Virus
6.2.3 Market Forecast
7 Market Breakup by Application
7.1 Solid Tumors
7.1.1 Market Trends
7.1.2 Key Segments
7.1.2.1 Breast Cancer
7.1.2.2 Prostate Cancer
7.1.2.3 Lung Cancer
7.1.2.4 Glioblastoma
7.1.3 Market Forecast
7.2 Melanoma
7.2.1 Market Trends
7.2.2 Key Segments
7.2.2.1 Hematological Malignancies
7.2.2.2 Lymphoma
7.2.2.3 Leukemia
7.2.2.4 Myeloma
7.2.3 Market Forecast
8 Market Breakup by End Use
8.1 Hospitals
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Specialty Clinics
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Cancer Research Institute
8.3.1 Market Trends
8.3.2 Market Forecast
9 Market Breakup by Region
9.1 North America
9.1.1 United States
9.1.1.1 Market Trends
9.1.1.2 Market Forecast
9.1.2 Canada
9.1.2.1 Market Trends
9.1.2.2 Market Forecast
9.2 Asia-Pacific
9.2.1 China
9.2.1.1 Market Trends
9.2.1.2 Market Forecast
9.2.2 Japan
9.2.2.1 Market Trends
9.2.2.2 Market Forecast
9.2.3 India
9.2.3.1 Market Trends
9.2.3.2 Market Forecast
9.2.4 South Korea
9.2.4.1 Market Trends
9.2.4.2 Market Forecast
9.2.5 Australia
9.2.5.1 Market Trends
9.2.5.2 Market Forecast
9.2.6 Indonesia
9.2.6.1 Market Trends
9.2.6.2 Market Forecast
9.2.7 Others
9.2.7.1 Market Trends
9.2.7.2 Market Forecast
9.3 Europe
9.3.1 Germany
9.3.1.1 Market Trends
9.3.1.2 Market Forecast
9.3.2 France
9.3.2.1 Market Trends
9.3.2.2 Market Forecast
9.3.3 United Kingdom
9.3.3.1 Market Trends
9.3.3.2 Market Forecast
9.3.4 Italy
9.3.4.1 Market Trends
9.3.4.2 Market Forecast
9.3.5 Spain
9.3.5.1 Market Trends
9.3.5.2 Market Forecast
9.3.6 Russia
9.3.6.1 Market Trends
9.3.6.2 Market Forecast
9.3.7 Others
9.3.7.1 Market Trends
9.3.7.2 Market Forecast
9.4 Latin America
9.4.1 Brazil
9.4.1.1 Market Trends
9.4.1.2 Market Forecast
9.4.2 Mexico
9.4.2.1 Market Trends
9.4.2.2 Market Forecast
9.4.3 Others
9.4.3.1 Market Trends
9.4.3.2 Market Forecast
9.5 Middle East and Africa
9.5.1 Market Trends
9.5.2 Market Breakup by Country
9.5.3 Market Forecast
10 SWOT Analysis
10.1 Overview
10.2 Strengths
10.3 Weaknesses
10.4 Opportunities
10.5 Threats
11 Value Chain Analysis
12 Porters Five Forces Analysis
12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
14.3.1 Amgen Inc.
14.3.1.1 Company Overview
14.3.1.2 Product Portfolio
14.3.1.3 Financials
14.3.1.4 SWOT Analysis
14.3.2 Dnatrix Inc.
14.3.2.1 Company Overview
14.3.2.2 Product Portfolio
14.3.3 Genelux Corporation
14.3.3.1 Company Overview
14.3.3.2 Product Portfolio
14.3.4 Lokon Pharma AB
14.3.4.1 Company Overview
14.3.4.2 Product Portfolio
14.3.5 Replimune Group Inc.
14.3.5.1 Company Overview
14.3.5.2 Product Portfolio
14.3.6 Rigvir Ltd.
14.3.6.1 Company Overview
14.3.6.2 Product Portfolio
14.3.7 Sorrento Therapeutics
14.3.7.1 Company Overview
14.3.7.2 Product Portfolio
14.3.7.3 Financials
14.3.8 Takara Bio Inc. (Takara Holdings Inc.)
14.3.8.1 Company Overview
14.3.8.2 Product Portfolio
14.3.8.3 Financials
14.3.9 Targovax
14.3.9.1 Company Overview
14.3.9.2 Product Portfolio
14.3.10 TILT Biotherapeutics Ltd
14.3.10.1 Company Overview
14.3.10.2 Product Portfolio
14.3.11 Transgene SA
14.3.11.1 Company Overview
14.3.11.2 Product Portfolio
14.3.11.3 Financials
14.3.12 Vyriad
14.3.12.1 Company Overview
14.3.12.2 Product Portfolio
Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings